Multiple-ascending doses of ACT-1014-6470, an oral complement factor 5a receptor 1 (C5a 1 receptor) antagonist: Tolerability, pharmacokinetics and target engagement.

Published in: British journal of clinical pharmacology (2022)

The compound was generally safe and well tolerated at all dose levels, warranting further clinical investigations.

Keyphrases